US · CMPX
Compass Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Boston, MA 02135
- Website
- compasstherapeutics.com
Price · as of 2024-12-31
$1.96
Market cap 781.32M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $1.52 | ||||
| 2022 | $3.32 | ||||
| 2023 | $1.96 | ||||
| 2024 | $2.69 |
AI valuation
Our deep-learning model estimates Compass Therapeutics, Inc.'s (CMPX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $1.96
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CMPX | Compass Therapeutics, Inc… | $1.96 | 781.32M | — | — | — | — | -7.47 | 2.95 | 433.91 | -4.53 | -82.17 | 2.95 | 100.00% | -6661.76% | -5808.82% | -36.07% | -3833.78% | -33.22% | 0.05 | — | 14.96 | 14.28 | 0.67 | 909.00% | — | 1046.00% | -12.17% | -5.05 | -3039.88% | 0.00% | 0.00% | 3.89% | -4.39 | -5.54 | 292.63 | 10.68 |
| BCYC | Bicycle Therapeutics plc | $5.73 | 397.02M | +373% | +110% | — | — | -3.52 | 0.75 | 16.88 | 1.67 | — | 0.75 | -390.34% | -594.96% | -479.18% | -29.04% | 217.72% | -21.78% | 0.01 | -121.31 | 13.81 | 13.61 | 5.28 | -4291.00% | 3076.00% | 16112.00% | -27.87% | -2.45 | 177.02% | 0.00% | 0.00% | 65.25% | 1.31 | 1.65 | -7.78 | 1.58 |
| CRVS | Corvus Pharmaceuticals, I… | $18.26 | 1.53B | — | — | — | — | -4.52 | 8.65 | — | -8.41 | -5.57 | 8.65 | 0.00% | — | — | -174.85% | 1026.95% | -108.85% | 0.03 | — | 1.54 | 1.47 | 0.28 | 8124.00% | — | 607.00% | -9.02% | -0.72 | 947.77% | 0.00% | 0.00% | 0.00% | -8.38 | -9.08 | — | -4.40 |
| FDMT | 4D Molecular Therapeutics… | $9.66 | 492.74M | +142% | -52% | — | +2,596% | -1.36 | 0.43 | 5933.81 | 1.00 | -8.80 | 0.43 | 100.00% | -507678.38% | -434778.38% | -39.31% | -259.80% | -35.74% | 0.05 | — | 14.92 | 14.58 | 0.69 | 1550.00% | -9982.00% | 7613.00% | -63.02% | -4.62 | -191.38% | 0.00% | 0.00% | 0.00% | 0.96 | 1.31 | -4884.32 | 0.97 |
| FULC | Fulcrum Therapeutics, Inc… | $8.38 | 453.45M | +452% | — | — | — | -6.61 | 1.42 | — | -2.03 | -1.04 | 1.42 | 0.00% | — | — | -25.30% | -1230.41% | -23.89% | 0.02 | — | 27.40 | 27.00 | 2.60 | 63750.00% | -10000.00% | 231903.00% | -12.20% | -4.60 | -876.39% | 0.00% | 0.00% | 28.60% | -1.76 | -2.47 | — | 15.27 |
| GOSS | Gossamer Bio, Inc. | $0.42 | 98.35M | — | +201% | — | — | -4.84 | 9.28 | 2.39 | -4.56 | — | 9.28 | 100.00% | -52.24% | -49.28% | -122.54% | 143.80% | -18.03% | 6.88 | -5.20 | 6.88 | 6.66 | -3.92 | -7881.00% | — | -9782.00% | -1.27% | -0.08 | 8.32% | 0.00% | 0.00% | 8.83% | -3.04 | -52.51 | 1.59 | -4.31 |
| KALV | KalVista Pharmaceuticals,… | $16.28 | 822.89M | — | — | — | — | -3.93 | 7.56 | — | -3.11 | -54.08 | 7.56 | 0.00% | — | — | -121.50% | 456.02% | -75.46% | 0.07 | -32.50 | 5.35 | 4.49 | 0.53 | 727.00% | — | 7100.00% | -21.27% | -3.39 | 371.96% | 0.00% | 0.00% | 9.41% | -2.87 | -3.52 | — | -2.40 |
| LXRX | Lexicon Pharmaceuticals, … | $1.47 | 581.34M | +24,271% | +1,124% | — | — | -0.62 | 0.86 | 4.02 | 0.03 | — | 1.23 | 98.02% | -634.20% | -644.78% | -167.66% | -865.73% | -75.93% | 0.74 | -12.65 | 5.44 | 5.34 | -0.23 | -2125.00% | 248148.00% | 1074.00% | -144.07% | -3.95 | -789.72% | 0.00% | 0.00% | 34.92% | 0.02 | 0.03 | -0.15 | -10.01 |
| MNPR | Monopar Therapeutics Inc. | $54.81 | 366.24M | — | — | — | — | -20.88 | 5.91 | — | -16.41 | -15.53 | 5.91 | 0.00% | — | — | -51.42% | 471.62% | -46.09% | 0.00 | — | 11.47 | 11.46 | 2.83 | 13448.00% | — | -1850.00% | -1.97% | -1.22 | 186.88% | 0.00% | 0.00% | 11.85% | -16.41 | -41.42 | — | 35.62 |
| OCGN | Ocugen, Inc. | $1.82 | 595.72M | +1,481% | -87% | — | +155% | -3.06 | 5.58 | 40.77 | -2.64 | — | 5.58 | 51.47% | -1350.36% | -1333.02% | -154.01% | -938.91% | -73.55% | 1.10 | — | 2.86 | 2.71 | 0.49 | -2308.00% | -3282.00% | -3723.00% | -27.54% | -1.95 | -780.64% | 0.00% | 0.00% | 0.00% | -2.54 | -3.06 | 34.35 | -5.46 |
| OMER | Omeros Corporation | $12.05 | 854.35M | — | — | — | — | -2.84 | -2.44 | — | -3.58 | -6.51 | -2.44 | 0.00% | — | — | 151.08% | -341.82% | -47.86% | -1.13 | -6.86 | 1.69 | 1.60 | -1.30 | 4362.00% | — | -30050.00% | -33.43% | -1.87 | -300.85% | 0.00% | 0.00% | 36.52% | -3.32 | -3.78 | — | -5.80 |
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
- CEO
- Thomas J. Schuetz
- Employees
- 35
- Beta
- 1.27
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.96) − 1 = — (DCF, example).